Hantz Financial Services Inc. reduced its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 12.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,690 shares of the company’s stock after selling 2,920 shares during the period. Hantz Financial Services Inc.’s holdings in AstraZeneca were worth $3,341,000 as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Roxbury Financial LLC acquired a new stake in shares of AstraZeneca in the second quarter valued at about $29,000. Resources Management Corp CT ADV acquired a new position in AstraZeneca during the first quarter worth about $35,000. Allied Private Wealth LLC acquired a new position in AstraZeneca during the second quarter worth about $35,000. Laurel Wealth Advisors LLC acquired a new stake in shares of AstraZeneca during the 3rd quarter valued at approximately $30,000. Finally, GK Wealth Management LLC purchased a new stake in shares of AstraZeneca during the 3rd quarter worth approximately $31,000. Institutional investors and hedge funds own 20.35% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have weighed in on AZN. Citigroup reissued a “buy” rating on shares of AstraZeneca in a report on Tuesday, October 6th. Nordea Equity Research raised AstraZeneca from a “sell” rating to a “buy” rating in a research note on Tuesday, October 13th. Royal Bank Of Canada began coverage on shares of AstraZeneca in a research report on Tuesday, September 8th. They issued an “outperform” rating on the stock. Weiss Ratings upgraded shares of AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 26th. Finally, Zacks Research raised shares of AstraZeneca from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 13th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $206.67.
Key AstraZeneca News
These are some of the AZN news items that stood out recently:
- Positive Sentiment: The U.S. and EU approved Klygefa for generalized myasthenia gravis. Its once-weekly dosing may offer patients greater convenience and gives AstraZeneca another commercial opportunity. AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa
- Positive Sentiment: AstraZeneca fended off a lawsuit alleging it monopolized the market for Soliris, reducing a legal overhang. Separately, Baxfendy was recommended for EU approval after Phase III hypertension trials, a further pipeline milestone. AstraZeneca fends off lawsuit over alleged Soliris drug monopoly AstraZeneca’s Baxfendy Recommended for EU Approval
- Neutral Sentiment: AstraZeneca is cutting 600 U.S. sales jobs as a cost-saving program takes effect. Lower expenses could help margins, though the restructuring may bring operational changes. AstraZeneca Cuts 600 U.S. Sales Jobs
AstraZeneca Stock Performance
NYSE:AZN opened at $182.23 on Wednesday. The firm has a 50 day simple moving average of $169.69 and a 200-day simple moving average of $180.18. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.01 and a quick ratio of 0.79. The firm has a market cap of $282.62 billion, a PE ratio of 18.18, a P/E/G ratio of 1.43 and a beta of 0.24. AstraZeneca Plc has a 1-year low of $153.41 and a 1-year high of $212.71.
AstraZeneca (NYSE:AZN – Get Free Report) last announced its quarterly earnings data on Saturday, October 31st. The company reported $2.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.60 by $0.19. The business had revenue of $16.21 billion for the quarter, compared to the consensus estimate of $16 billion. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The company’s quarterly revenue was up 6.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.38 earnings per share. On average, equities analysts expect that AstraZeneca Plc will post 10.22 EPS for the current year.
AstraZeneca Profile
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Featured Stories
- Five stocks we like better than AstraZeneca
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
